Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Opdivo plus Cabometyx reduced the risk of death by 40%.
Among patients with high tumor PD-L1 expression, Libtayo lowered mortality by 43%.
A checkpoint inhibitor combination and an antibody-drug conjugate may offer new treatment options.
The 30% improvement in survival has brought a Phase III trial to an early halt.
Adding Tecentriq to a three-drug chemotherapy regimen increases odds of remission of early-stage triple-negative breast cancer.
Opdivo and Keytruda are potential alternatives to current first-line therapies.
The oral targeted therapy lowered the risk of relapse in a late-stage study.
The antibody-drug conjugate nearly doubled survival time for people with triple-negative breast cancer.
The drug also showed promise for colorectal and other cancers, but it might work better in combination regimens.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.